Skip to main content

Table 2 Frequencies of anti-PM/Scl antibodies in disease subsets

From: Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma

Frequencies of anti-PM/Scl antibodies in disease subsets
Study Marguerie Mahler Rozman Hanke Maes
Reference [13] [39] [40] [41] [42]
Year 1992 2005 2008 2009 2010
Country UK Various Europe Germany Belgium
Anti-PM/Scl detection CIE PM1-α ELISA LIA LIA PM1-α ELISA
Patient selection and numbers of patients 1689 SLE 205 SSc 625 SSc 280 SScb 70 SSc
879 SSca 114 SLE   88 RA 66 SLE
256 PM or DM 40 PM   72 SLE 35 SS
  40 PM/SSc   49 SS 24 RA
     23 DM
     13 PM
     11 MCTD
Anti-PM/Scl-positive patients 27 PM (or DM)/SSc 22 PM/SSc (55%) 1 PM (7.7%) Anti-PM/Scl-75 Anti-PM/Scl-100 3 SSc (4.3%)
  4 SSc 27 SSc (13%) 18 SSc (2.9%) 29 SSc (10%) 20 SSc (7.1%)  
  1 PM 3 PM (7.5%) 1 DM (1.7%) 3 RA (3.4%) 3 SLE (4.2%)  
     1 SLE (1.4%) 1 SS (2.0%)  
Study Mierau Koschik Mehra D’Aoust Kazi Muro
Reference [31] [57] [58] [17] [18] The present study
Year 2011 2012 2013 2014 2014  
Country Germany USA Australia Canada Japan Japan
Anti-PM/Scl detection ID ID LIA PM1-α ELISA IIP ELISA, IPP
Patient selection and numbers of patients 863 SSc 2425 SSc 528 SSc 763 SSc Kanazawa cohort 223 SSc
      316 SSc 126 DM
      Keio cohort 123 SLE
      272 SSc 88 SS
       17 overlap
       16 UCTD
       7 PM
Anti-PM/Scl-positive patients 42 SSc (4.9%) 75 SSc (3.1%) Anti-PM/Scl-75 55 SSc (7.2%) 0 4 UCTD (25%)
    66 SSc (12.5%)    3 DM (2.4%)
    Anti-PM/Scl-100    1 SS (1.1%)
    26 SSc (4.9%)    1 SSc (0.4%)
  1. aSince the numbers of myositis overlap patients were not given, the frequencies of the antibodies in disease subsets were not calculated; b51 overlap and 16 undifferentiated connective tissue disease patients were included.
  2. CIE, counter immunoelectrophoresis; DM, dermatomyositis; ID, immunodiffusion; IPP, immunoprecipitation; LIA, line immunoassay; MCTD, mixed connective tissue disease; PM, polymyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSc, systemic scleroderma; UCTD, undifferentiated connective tissue disease.